Evaluate the Efficacy and Safety to Tenofovir Disoproxil in Chronic Hepatitis B Patients

Inclusion Criteria: * Chronic hepatitis B virus (HBV) infection, defined as positive serum hepatitis B s-antigen (HBsAg) for at least 6 months. * HBeAg negative and HBeAb positive at screening Exclusion Criteria: * Pregnant women, women who are breast feeding, or women who believe they may wish to become pregnant during the course of the study * Males and females of reproductive potential who are unwilling to use an effective method of contraception during the study. * Decompensated liver disease defined as conjugated bilirubin \> 1.5 x ULN, prothrombin time (PT) \> 1.5 x ULN, platelets \< 75,000/mL, serum albumin \< 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage) * Significant renal, cardiovascular, pulmonary, or neurological disease * currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion